(:MNLO)

Sep 09, 2020 08:00 am ET
VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September
VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual...
Sep 08, 2020 08:00 am ET
Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics
VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from “MNLO” to “VYNE”.  The...
Sep 02, 2020 08:00 am ET
Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today it is changing its corporate name to VYNE Therapeutics Inc.  (“VYNE Therapeutics”). In connection with the name change, the Company’s common stock will begin trading...
Aug 06, 2020 07:00 am ET
Menlo Reports Second Quarter 2020 Financial Results and Provides Business Update
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced financial results for the...
Jul 28, 2020 08:00 am ET
Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August 6
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it will report its...
Jun 05, 2020 07:00 am ET
Menlo Therapeutics Announces Pricing of Offering of Common Stock
Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the pricing of an underwritten public...
Jun 04, 2020 04:01 pm ET
Menlo Therapeutics Announces Proposed Offering of Common Stock
Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it intends to offer and sell, subject...
Jun 02, 2020 08:00 am ET
Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced positive results from a...
May 29, 2020 11:49 am ET
Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea
BRIDGEWATER, N.J., May 29, 2020 /PRNewswire/ -- Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved ZILXI™ (minocycline) topical foam, 1.5%, for the treatment of inflammatory lesions of rosacea in adults. ZILXI, developed as FMX103 by Menlo's wholly-owned subsidiary Foamix Pharmaceuticals Ltd. ("Foamix"), is the first minocycline product of any kind to be approved
May 29, 2020 11:38 am ET
Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that the U.S. Food and Drug...
May 27, 2020 08:00 am ET
Menlo Therapeutics Announces Covered Status for AMZEEQ® (minocycline) topical foam, 4%, on Additional Commercial Formulary
Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that its novel AMZEEQ®...
May 26, 2020 08:00 am ET
Menlo Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief...
May 22, 2020 08:30 am ET
Robbins Geller Rudman & Dowd LLP Announce Proposed Settlement in the Menlo Therapeutics Inc. Securities Settlement
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Menlo Therapeutics Inc. Securities Settlement:
May 11, 2020 07:00 am ET
Menlo Reports First Quarter 2020 Financial Results and Provides Business Update
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced financial results for the...
May 05, 2020 08:00 am ET
Menlo Therapeutics to Report First Quarter 2020 Financial Results on May 11
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it will report its...
Apr 23, 2020 08:00 am ET
Menlo Therapeutics and Cutia Therapeutics Enter into Exclusive License Agreement for AMZEEQ™ and Approved Topical Minocycline Products in Greater China
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that its wholly-owned...
Apr 06, 2020 07:00 am ET
Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo Nodularis
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced top line results from two Phase 3...
Apr 02, 2020 08:00 am ET
Menlo Announces Settlement to Conclude Finacea Foam Litigation and Announces that Partner, LEO Pharma A/S, Remedies Finacea Foam Supply Issues
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that its wholly-owned subsidiary,...
Mar 24, 2020 08:00 am ET
Menlo Therapeutics Appoints Andrew Saik as Chief Financial Officer
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, appointed Andrew Saik as Chief Financial Officer...
Mar 20, 2020 08:00 am ET
Menlo Therapeutics Provides a Business Update in the Context of COVID-19
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today provided a business update in the context of...
Mar 12, 2020 07:00 am ET
Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced financial results for its...
Mar 09, 2020 08:00 am ET
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix”) following the satisfaction of all closing conditions required by the merger...
Mar 03, 2020 04:05 pm ET
Menlo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the fourth quarter and year ended December 31, 2019...
Feb 26, 2020 07:30 am ET
Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin
Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced results from its Phase 2 clinical trial evaluating the safety and efficacy of once daily oral serlopitant for the treatment of chronic pruritus (itch)...
Feb 25, 2020 07:01 pm ET
Menlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin
Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET (5:30 am PT) to discuss results from the Phase 2 trial of...
Feb 06, 2020 01:00 pm ET
Foamix and Menlo Announce Shareholder Approval of Proposed Merger
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and stockholder proposals necessary to complete the...
Feb 06, 2020 01:00 pm ET
Foamix and Menlo Announce Shareholder Approval of Proposed Merger
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and stockholder proposals necessary to complete the...
Feb 05, 2020 08:30 am ET
Menlo Therapeutics Announces Publication of Phase 2 Results for Serlopitant for the Treatment of Pruritus Associated with Psoriasis in the Journal of the American Academy of Dermatology
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company’s Phase 2 trial of serlopitant for the...
Nov 27, 2019 08:00 am ET
Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare Conference
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, chief executive officer of Menlo Therapeutics, will...
Nov 13, 2019 04:34 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Menlo Therapeutics Inc. with Foamix Pharmaceuticals Ltd. is Fair to MNLO Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Menlo Therapeutics Inc. (“Menlo” or the “Company”) (NASDAQ: MNLO) stock prior to November 11, 2019. You are hereby notified that Levi &...
Nov 12, 2019 04:09 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.
NEW YORK, Nov. 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foamix Pharmaceuticals Ltd. ("FOMX" or the "Company") (NASDAQ: FOMX) in connection with the proposed acquisition of the Company by Menlo Therapeutics, Inc. ("MNLO") (NASDAQ: MNLO).  Under the terms of the acquisition agreement, FOMX shareholders will receive 0.5924 shares of MNLO and a contingent stock right for each FOMX share they own.
Nov 11, 2019 06:00 am ET
Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) (“Foamix”) and Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo”) today announced that they have signed a definitive merger agreement to create a combined biopharmaceutical company focused on the...
Nov 11, 2019 06:00 am ET
Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) (“Foamix”) and Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo”) today announced that they have signed a definitive merger agreement to create a combined biopharmaceutical company focused on the...
Oct 31, 2019 04:05 pm ET
Menlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program Updates
Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the third quarter ended September 30, 2019 and...
Oct 29, 2019 07:00 am ET
Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis
Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced that it has completed enrollment of patients in its two Phase 3 clinical trials evaluating the safety and efficacy of once daily oral serlopitant for...
Oct 22, 2019 08:30 am ET
Menlo Therapeutics to Host Investor Day October 29, 2019
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company, announced that the company will host an Investor Day on Tuesday, October 29th, 8:00–11:00 am ET. The event will focus on a review of Menlo’s clinical programs,...
Oct 11, 2019 08:30 am ET
Menlo Therapeutics Presents Successful Phase 2 Clinical Trial Results of Serlopitant in Psoriasis at the European Academy of Dermatology and Venereology Meeting
Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical trial of serlopitant for the treatment of pruritis in patients with psoriasis in an oral presentation at the...
Sep 26, 2019 04:05 pm ET
Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steven Basta, chief executive officer of Menlo Therapeutics, will...
Sep 24, 2019 04:05 pm ET
Menlo Therapeutics Announces Completion of Enrollment of 233 Patients in Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin
Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced that it has completed patient enrollment in its Phase 2 clinical trial evaluating the safety and efficacy of once daily oral serlopitant for the...
Aug 29, 2019 04:05 pm ET
Menlo Therapeutics to Present at the HC Wainwright 21st Annual Global Investment Conference
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Kristine Ball, chief financial officer of Menlo Therapeutics, will...
Aug 01, 2019 04:05 pm ET
Menlo Therapeutics Reports Second Quarter 2019 Financial Results and Provides Program Updates Including Accelerated Timeline for Upcoming Clinical Data
Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the second quarter ended June 30, 2019 and provided...
Jul 31, 2019 08:30 am ET
Menlo Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Menlo’s Chief Executive Officer, will present at the...
Jul 15, 2019 08:35 am ET
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Jul 15, 2019 08:35 am ET
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing
NEW YORK, July 15, 2019 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the July 11th life sciences conference are now available for on-demand viewing at VirtualInvestorConferences.com.
Jul 09, 2019 12:03 pm ET
Life Science Company Live Investor Conference July 11th
NEW YORK, July 9, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming Virtual lnvestor Conference, the leading proprietary investor conference series.  Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:15 AM ET, with the first live webcast at 9:30 AM ET, on Thursday, July 11th.
Jul 09, 2019 12:00 pm ET
Life Science Company Live Investor Conference July 11th
Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com
Jun 18, 2019 08:30 am ET
Menlo Therapeutics Announces Addition of Ronald A. Krasnow as General Counsel and Chief Compliance Officer
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the hiring of Ronald A. Krasnow as General Counsel and Chief Compliance...
May 29, 2019 08:30 am ET
Menlo Therapeutics to Present at Upcoming Investor Conferences
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive Officer, will present at the following...
May 13, 2019 06:21 pm ET
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Menlo Therapeutics, Inc. (“Menlo” or the “Company”) (NASDAQGS: MNLO) pursuant or traceable to the...
May 02, 2019 04:05 pm ET
Menlo Therapeutics Reports First Quarter 2019 Financial Results
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the first quarter ended March 31, 2019 and provided...
Apr 22, 2019 08:30 am ET
Menlo Therapeutics to Present at the Class of 2018 Biotech IPOs Investor Day
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive Officer, will present at the Class of...
Apr 03, 2019 07:25 am ET
New Research: Key Drivers of Growth for Geron, Hess, Royal Gold, Lear, Menlo Therapeutics, and CorEnergy Infrastructure Trust — Factors of Influence, Major Initiatives and Sustained Production
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Geron Corporation (NASDAQ:GERN), Hess Corporation (NYSE:HES), Royal Gold,...
Mar 25, 2019 08:30 am ET
Menlo Therapeutics Announces Publication of Serlopitant Phase 2 Data for the Treatment of Pruritus Associated with Prurigo Nodularis
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company’s Phase 2 trial of serlopitant for the...
Mar 20, 2019 08:30 am ET
Menlo Therapeutics Announces New Board Member Elisabeth Sandoval
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Elisabeth Sandoval has been appointed as a member of Menlo’s Board...
Mar 11, 2019 08:30 am ET
Menlo Therapeutics to Present at the 31st Annual ROTH Conference
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that management will present at the 31st Annual ROTH Conference on...
Feb 27, 2019 04:05 pm ET
Menlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the fourth quarter and year ended December 31, 2018...
Feb 26, 2019 03:25 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Menlo Therapeutics, Inc. (“Menlo” or the “Company”) (NASDAQGS: MNLO) pursuant or traceable to the...
Jan 29, 2019 08:30 am ET
Menlo Therapeutics Announces Late-Breaking Oral Presentation at the American Academy of Dermatology Annual Meeting
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that an abstract has been accepted for oral presentation at the...
Jan 29, 2019 07:25 am ET
Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics — Future Expectations, Projections Moving i
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Incyte Corporation (NASDAQ:INCY), Burlington Stores, Inc. (NYSE:BURL),...
Jan 15, 2019 08:30 am ET
Menlo Therapeutics’ Serlopitant Granted Breakthrough Therapy Designation by FDA for the Treatment of Pruritus Associated with Prurigo Nodularis
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
Jan 14, 2019 09:35 am ET
Lawsuit for Investors in NASDAQ: MNLO shares against Menlo Therapeutics Inc. announced by Shareholders Foundation
The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: MNLO shares over alleged securities laws violations by Menlo Therapeutics Inc. in connection with the Company’s Initial Public Offering (“IPO”)....
Dec 19, 2018 04:21 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Menlo Therapeutics, Inc. (“Menlo” or the “Company”) (NASDAQGS: MNLO) pursuant or traceable to the...
Dec 14, 2018 10:11 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Menlo Therapeutics, Inc. (“Menlo” or the “Company”) (NASDAQGS: MNLO) pursuant or traceable to the...
Dec 13, 2018 02:00 pm ET
Robbins Arroyo LLP: Menlo Therapeutics Inc. (MNLO) Misled Shareholders According to Class Action
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Menlo Therapeutics Inc. (NasdaqGS: MNLO) filed a class action complaint against the company's officers and directors for alleged violations of the Securities Act of 1933 in connection with Menlo's January 29, 2018 initial public
Dec 12, 2018 07:45 am ET
Market Trends Toward New Normal in Apptio, Menlo Therapeutics, Tanger Factory Outlet Centers, Cedar Realty Trust, Toll Brothers, and II-VI — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Apptio Inc. (NASDAQ:APTI), Menlo Therapeutics Inc. (NASDAQ:MNLO),...
Dec 11, 2018 12:29 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Menlo Therapeutics, Inc.
Levi & Korsinsky announces it has commenced an investigation of Menlo Therapeutics, Inc. (“Menlo” or “the Company”) (NASDAQGS: MNLO) concerning possible violations of federal securities laws. To obtain additional information, go to:...
Dec 10, 2018 07:00 am ET
Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced positive top-line results from MTI-109 (PSORIXA), a 204-patient Phase 2...
Nov 28, 2018 08:50 am ET
Report: Developing Opportunities within Liberty TripAdvisor, Chanticleer, Retrophin, Menlo Therapeutics, Shire plc, and Matthews International — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Liberty TripAdvisor Holdings, Inc. (NASDAQ:LTRPA), Chanticleer...
Nov 16, 2018 08:30 am ET
Menlo Therapeutics to Participate in the 30th Annual Piper Jaffray Healthcare Conference
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various conditions, today announced that Steve Basta, Chief Executive Officer,...
Nov 14, 2018 03:02 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Menlo Therapeutics, Inc.
Levi & Korsinsky announces it has commenced an investigation of Menlo Therapeutics, Inc. (“Menlo” or “the Company”) (NASDAQGS: MNLO) concerning possible violations of federal securities laws. To obtain additional information, go to:...
Nov 07, 2018 04:05 pm ET
Menlo Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various conditions, today announced financial results for the third quarter ended...
Nov 05, 2018 06:46 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating Seaboard, Menlo, Super Micro, and NiSource on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Seaboard Corporation, Menlo Therapeutics Inc., Super Micro Computer, Inc., and NiSource Inc.  Additional information about each...
Oct 23, 2018 11:39 am ET
Scott+Scott Attorneys at Law LLP Announces Investigation into Menlo Therapeutics Inc. (MNLO)
NEW YORK, Oct. 23, 2018 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether Menlo Therapeutics Inc. ("Menlo" or the "Company") (NASDAQ: MNLO) or certain of its officers and directors violated federal securities laws.  If you purchased Menlo stock in or after the Company's January 2018 initial public offering ("IPO"), you are encouraged to contact a Scott+Scott attorney at (844) 818-6982 for more information.
Oct 22, 2018 10:00 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Menlo Therapeutics Inc. (MNLO)
Attorney Advertising -- Bronstein, Gewirtz Grossman, LLC is investigating potential claims on behalf of purchasers of Menlo Therapeutics Inc. (“Menlo” or the “Company”) (NASDAQ: MNLO). Such investors are encouraged to obtain additional...
Oct 17, 2018 09:15 am ET
Analysis: Positioning to Benefit within Matrix Service, Mersana Therapeutics, Quorum Health, Canopy Growth, Bristow Group, and Menlo Therapeutics — Research Highlights Growth, Revenue, and Consolidate
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Matrix Service Company (NASDAQ:MTRX), Mersana Therapeutics, Inc....
Oct 08, 2018 08:00 am ET
Menlo Therapeutics Announces Results from a Phase 2 Clinical Trial of Serlopitant for the Treatment of Refractory Chronic Cough
Menlo Therapeutics Inc. (NASDAQ: MNLO) a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various conditions, today announced top-line results from MTI-110 (TUSSIX), its...
Oct 05, 2018 08:01 pm ET
Johnson Fistel Announces Investigations of PPDAI Group Inc., Menlo Therapeutics Inc., Eyenovia, Inc. and Dragon Victory International Limited; Investors with Losses Encouraged to Contact Firm
SAN DIEGO, Oct. 5, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against:
Sep 24, 2018 07:22 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating Possible Securities Fraud Violations by Certain Officers and Directors of Menlo Therapeutics, Hill International, and Eyenovia on
Bragar Eagel Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Menlo Therapeutics Inc., Hill International, Inc., and Eyenovia, Inc.  Additional information about each potential action can be...
Sep 17, 2018 08:30 am ET
Menlo Therapeutics Begins European Prurigo Nodularis Phase 3 Trial and Presents Additional Data from PN Phase 2 Trial at EADV
Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various conditions and for refractory chronic cough, today announced it has...
Aug 23, 2018 07:35 am ET
Consolidated Research: 2018 Summary Expectations for SpartanNash, Encana, Hilltop, Pacira Pharmaceuticals, Menlo Therapeutics, and Rayonier Advanced Materials — Fundamental Analysis, Key Performance I
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SpartanNash Company (NASDAQ:SPTN), Encana Corporation (NYSE:ECA), Hilltop...
Aug 15, 2018 02:22 pm ET
Scott+Scott Attorneys at Law LLP Reminds Investors of its Investigation into Menlo Therapeutics Inc. (MNLO)
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, is investigating whether Menlo Therapeutics Inc. (“Menlo” or the “Company”) (NASDAQ: MNLO) or certain of its officers and directors violated federal securities laws. If you purcha
Aug 10, 2018 04:35 pm ET
Investigation On Behalf Of Menlo Therapeutics Shareholders For Recovery Of Investment Losses
BOSTON, Aug. 10, 2018 /CNW/ -- Thornton Law Firm LLP is investigating a potential lawsuit on behalf of purchasers of the securities of Menlo Therapeutics Inc. (NASDAQ: MNLO) pursuant or traceable to the registration statement and prospectus issued in connection with Menlo's January 2018 initial public offering ("IPO"). The lawsuit seeks to recover damages for Menlo investors/shareholders under the federal securities laws. MNLO stock has dropped significantly after recent revelations that Menlo's leading product, serlopitant, is no better than a placebo at treating certain skin conditions.
Aug 10, 2018 04:35 pm ET
Investigation On Behalf Of Menlo Therapeutics Shareholders For Recovery Of Investment Losses
BOSTON, Aug. 10, 2018 /PRNewswire/ -- Thornton Law Firm LLP is investigating a potential lawsuit on behalf of purchasers of the securities of Menlo Therapeutics Inc. (NASDAQ: MNLO) pursuant or traceable to the registration statement and prospectus issued in connection with Menlo's January 2018 initial public offering ("IPO"). The lawsuit seeks to recover damages for Menlo investors/shareholders under the federal securities laws. MNLO stock has dropped significantly after recent revelations that Menlo's leading product, serlopitant, is no better than a placebo at treating certain skin conditi
Aug 02, 2018 05:57 pm ET
Bragar Eagel & Squire, P.C. is Investigating Menlo Therapeutics Inc. (MNLO) on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel Squire, P.C. is investigating potential claims against Menlo Therapeutics Inc. (NASDAQ: MNLO).  Our investigation concerns whether Menlo has violated the federal securities laws and/or engaged in other unlawful business practices....
Aug 01, 2018 04:09 pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Menlo Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Menlo Therapeutics Inc. (“Menlo Therapeutics” or “the Company”) (NASDAQ:
Aug 01, 2018 04:05 pm ET
Menlo Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various conditions and for refractory chronic cough, today announced financial...
Aug 01, 2018 10:10 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Menlo Therapeutics Inc. (MNLO)
NEW YORK, Aug. 1, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Menlo Therapeutics Inc. ("Menlo" or the "Company") (NASDAQ: MNLO). Shareholders who purchased Menlo stock in or after the Company's January 2018 initial public offering ("IPO"), are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mnlo.
Jul 31, 2018 12:52 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Menlo Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Menlo Therapeutics Inc. (“Menlo Therapeutics” or “the Company”) (NASDAQ:
Jul 31, 2018 11:28 am ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Menlo Therapeutics Inc. – MNLO
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Menlo Therapeutics Inc. (NASDAQ: MNLO) resulting from allegations that Menlo may have issued materially misleading business information to the investing public.
Jul 18, 2018 09:50 am ET
Scott+Scott Attorneys at Law LLP Reminds Investors of its Investigation into Menlo Therapeutics Inc. (MNLO)
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, is investigating whether Menlo Therapeutics Inc. (“Menlo” or the “Company”) (NASDAQ: MNLO) or certain of its officers and directors violated federal securities laws. If you purcha
Jun 19, 2018 10:47 am ET
Scott+Scott Attorneys at Law LLP Announces Investigation into Menlo Therapeutics Inc. (MNLO)
NEW YORK, June 19, 2018 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether Menlo Therapeutics Inc. ("Menlo" or the "Company") (NASDAQ: MNLO) or certain of its officers and directors violated federal securities laws.  If you purchased Menlo stock in or after the Company's January 2018 initial public offering ("IPO"), you are encouraged to contact a Scott+Scott attorney at (844) 818-6982 for more information.
Jun 14, 2018 08:15 am ET
Detailed Research: Economic Perspectives on Verizon Communications, PayPal, Menlo Therapeutics, iClick Interactive Asia Group, BioTime, and Adobe — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Verizon Communications Inc. (NYSE:VZ), PayPal Holdings, Inc....
May 31, 2018 05:00 pm ET
Menlo Therapeutics to Present at Upcoming Investor Conferences
Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough, today...
May 21, 2018 08:30 am ET
Stanford Researchers Presented Results from an Exploratory Study of Serlopitant for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients Indicating Reduction in Itch with Serlopitant Treatm
Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough, today...
May 09, 2018 04:05 pm ET
Menlo Therapeutics Reports First Quarter 2018 Financial Results
Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough, today...
May 07, 2018 08:30 am ET
Menlo Therapeutics Announces Senior Clinical Leadership Updates
Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough, today...
Apr 18, 2018 08:20 am ET
Detailed Research: Economic Perspectives on Menlo Therapeutics, Potbelly, Maximus, Veeva, RLJ Lodging Trust, and Net Element — What Drives Growth in Today's Competitive Landscape
NEW YORK, April 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Menlo Therapeutics Inc. (NASDAQ:MNLO), Potbelly Corporation...
Apr 08, 2018 06:00 pm ET
Mar 28, 2018 04:05 pm ET
Menlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
REDWOOD CITY, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic...
Feb 20, 2018 08:00 am ET
Menlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in the Journal of the American Academy of Dermatology
REDWOOD CITY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic...
Jan 29, 2018 09:30 am ET
Menlo Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
REDWOOD CITY, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO) today announced the closing of the Company’s initial public offering of 8,050,000 shares of common stock at a public offering price of $17.00 per share,...
Jan 24, 2018 08:47 pm ET
Menlo Therapeutics Inc. Announces Pricing of Initial Public Offering of Common Stock
REDWOOD CITY, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO) today announced the pricing of the Company’s initial public offering of 7,000,000 shares of common stock at a public offering price of $17.00 per share,...
Nov 21, 2017 08:00 am ET
Menlo Therapeutics Begins Phase 2 Clinical Trial for Pruritus Associated with Psoriasis
REDWOOD CITY, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc., a late-stage biopharmaceutical company developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) for the treatment of pruritus (itch) and refractory chronic cough, has initiated enrollment in...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.